Anti-EphA3 CAR-T cell therapy (Humanigen)

N/A

Report date: 2024/01/08 17:18:23

Base Information

Drug NameAnti-EphA3 CAR-T cell therapy (Humanigen)

Drug Alias NameIfabotuzumab anti-EphA3 CAR-T cell therapy (Humanigen)Anti-EphA3 immunotherapy (Humanigen)EphA3-CAR-T (Humanigen)

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Ephrin type-A receptor 3

TargetsEphrin type-A receptor 3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesHumanigen Inc

China Registration ClassN/A

Develop Information

Active CompaniesHumanigen Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A